Amyl Therapeutics raises €8.25M to advance first single-agent therapy targeting all amyloid diseases
Liège, Belgium — September 1, 2026 — Amyl Therapeutics (“Amyl Tx”), a preclinical-stage biotech developing a platform to treat amyloid-related neurodegenerative diseases,
